Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

51.17USD
20 Apr 2018
Change (% chg)

$-0.44 (-0.85%)
Prev Close
$51.61
Open
$51.62
Day's High
$51.85
Day's Low
$51.02
Volume
11,669,063
Avg. Vol
8,039,874
52-wk High
$70.05
52-wk Low
$51.02

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $83,664.20
Shares Outstanding(Mil.): 1,635.02
Dividend: 0.40
Yield (%): 3.13

Financials

  BMY Industry Sector
P/E (TTM): 21.70 31.01 33.60
EPS (TTM): 2.36 -- --
ROI: 15.94 13.60 13.19
ROE: 27.96 15.26 15.00

BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Opdivo In Previously Treated Patients With Small Cell Lung Cancer

* U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO (NIVOLUMAB) IN PREVIOUSLY TREATED PATIENTS WITH SMALL CELL LUNG CANCER AND GRANTS PRIORITY REVIEW

Apr 18 2018

BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors

* BRISTOL-MYERS SQUIBB ANNOUNCES WORLDWIDE COLLABORATION WITH JANSSEN TO DEVELOP & COMMERCIALIZE BRISTOL-MYERS' FACTOR XIA INHIBITOR, BMS-986177

Apr 16 2018

BRIEF-Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors

* JANSSEN ANNOUNCES WORLDWIDE DEVELOPMENT & COMMERCIALIZATION COLLABORATION WITH BRISTOL-MYERS TO ADVANCE THERAPY FOR CARDIOVASCULAR DISEASES

Apr 16 2018

BRIEF-Bristol-Myers Says Opdivo Demonstrated Sustained Overall Survival Advantage Over Standard Of Care In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

* IN CHECKMATE -141, OPDIVO (NIVOLUMAB) DEMONSTRATED SUSTAINED OVERALL SURVIVAL (OS) ADVANTAGE OVER STANDARD OF CARE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Apr 16 2018

BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA

Apr 16 2018

BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct

* OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB)

Apr 16 2018

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

Apr 16 2018

BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer

* OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON -SMALL CELL LUNG CANCER (NSCLC)

Apr 13 2018

BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies

* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES

Apr 13 2018

BRIEF-Bristol Myers Squibb And Harvard Announce New Fibrosis Research Collaboration

* BRISTOL-MYERS SQUIBB AND HARVARD ANNOUNCE NEW FIBROSIS RESEARCH COLLABORATION Source text for Eikon: Further company coverage:

Apr 12 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.66 -0.89
Pfizer Inc. (PFE.N) $36.63 +0.10
Merck & Co., Inc. (MRK.N) $58.83 +0.19
Sanofi SA (SASY.PA) €65.28 -0.32
AstraZeneca plc (AZN.L) 4,976.00 +20.50
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60
Eli Lilly And Co (LLY.N) $79.06 -0.69
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20

Earnings vs. Estimates